Form 8-K - Current report:
SEC Accession No. 0001193125-25-200742
Filing Date
2025-09-11
Accepted
2025-09-11 07:24:23
Documents
14
Period of Report
2025-09-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d12074d8k.htm   iXBRL 8-K 26155
2 EX-99.1 d12074dex991.htm EX-99.1 47084
  Complete submission text file 0001193125-25-200742.txt   225877

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kalv-20250911.xsd EX-101.SCH 3221
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE kalv-20250911_def.xml EX-101.DEF 13336
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE kalv-20250911_lab.xml EX-101.LAB 21785
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kalv-20250911_pre.xml EX-101.PRE 14092
16 EXTRACTED XBRL INSTANCE DOCUMENT d12074d8k_htm.xml XML 5233
Mailing Address 200 CROSSING BOULEVARD FRAMINGHAM MA 01702
Business Address 200 CROSSING BOULEVARD FRAMINGHAM MA 01702 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

EIN.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-36830 | Film No.: 251307196
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)